GLP-1 access, conference readouts and a CVS split: Biotech & Pharma

GLP-1 medicines ran through two of the week's releases. Eli Lilly and Company and Hims & Hers Health said eligible patients on the telehealth platform can obtain Zepbound and Foundayo at Lilly's self-pay prices, with Hims & Hers committing not to offer compounded copies. Allergan Aesthetics, an AbbVie company, reported Phase 4 data on aesthetic treatment in adults taking GLP-1 medications. Conference data also featured heavily: Johnson & Johnson issued two releases, on nipocalimab in Sjögren's disease ahead of ACR Convergence 2026 and on a pasritamig-based combination in prostate cancer at SITC 2026.

Among smaller biotechs, Pyxis Oncology and Q32 Bio reported third-quarter results and cash bolstered by 2026 offerings, and each laid out a pivotal or registration-directed program for 2027. The largest corporate item came from CVS Health, which said it intends to split into two publicly traded companies by the first half of 2028. Telix Pharmaceuticals joined the Thera4Care theranostics consortium in Europe.